Welcome to our dedicated page for Allbirds news (Ticker: $BIRD), a resource for investors and traders seeking the latest updates and insights on Allbirds stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Allbirds's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Allbirds's position in the market.
Allbirds, Inc. (NASDAQ: BIRD) reported Q1 2024 financial results with a 27.6% decrease in net revenue, improved gross margin, and a net loss of $27.3 million. The company is focused on its strategic transformation plan, achieving cost efficiencies and expanding internationally. Allbirds ended the quarter with $102.1 million in cash and no outstanding borrowings. The company reiterates full-year 2024 guidance with net revenue of $190-210 million and an adjusted EBITDA2 loss of $78-63 million.
